ICAD INC (ICAD) Stock Price, Forecast & Analysis
USA - NASDAQ:ICAD - US44934S2068 - Common Stock
ICAD Key Statistics, Chart & Performance
The current stock price of ICAD is 3.87 USD. In the past month the price increased by 1.04%. In the past year, price increased by 197.69%.
ICAD Latest News, Press Relases and Analysis
ICAD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 39.86 | 48.67B | ||
| DOCS | DOXIMITY INC-CLASS A | 31.07 | 9.54B | ||
| WAY | WAYSTAR HOLDING CORP | 27.54 | 7.04B | ||
| HTFL | HEARTFLOW INC | N/A | 2.98B | ||
| PHR | PHREESIA INC | N/A | 1.39B | ||
| CERT | CERTARA INC | 16.56 | 1.33B | ||
| SDGR | SCHRODINGER INC | N/A | 1.32B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.32B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.08B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 631.25 | 1.07B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.74 | 1.06B | ||
| CTEV | CLARITEV CORP | N/A | 965.47M |
Related stock screener links
About ICAD
Company Profile
iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 66 full-time employees. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.
Company Info
ICAD INC
98 Spit Brook Rd Ste 100
Nashua NEW HAMPSHIRE 03062 US
CEO: Michael Klein
Employees: 66
Phone: 16038825200
ICAD INC / ICAD FAQ
What does ICAD INC do?
iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 66 full-time employees. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.
What is the current price of ICAD stock?
The current stock price of ICAD is 3.87 USD. The price increased by 3.75% in the last trading session.
What is the dividend status of ICAD INC?
ICAD does not pay a dividend.
How is the ChartMill rating for ICAD INC?
ICAD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of ICAD stock?
ICAD INC (ICAD) operates in the Health Care sector and the Health Care Technology industry.
What is the market capitalization of ICAD stock?
ICAD INC (ICAD) has a market capitalization of 106.31M USD. This makes ICAD a Micro Cap stock.
ICAD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ICAD. When comparing the yearly performance of all stocks, ICAD is one of the better performing stocks in the market, outperforming 97.09% of all stocks.
ICAD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICAD. No worries on liquidiy or solvency for ICAD as it has an excellent financial health rating, but there are worries on the profitability.
ICAD Financial Highlights
Over the last trailing twelve months ICAD reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.24% | ||
| ROE | -16.98% | ||
| Debt/Equity | 0 |
ICAD Forecast & Estimates
10 analysts have analysed ICAD and the average price target is 3.57 USD. This implies a price decrease of -7.75% is expected in the next year compared to the current price of 3.87.
For the next year, analysts expect an EPS growth of 12.57% and a revenue growth 4.66% for ICAD